NCT01368211终止2 期
PRESS Pathogen Reduction Extended Storage Study PRESS (Pathogen Reduction Extended Storage Study) A Pilot Study of Mirasol Platelets Treated in Platelet Additive Solution in Thrombocytopenic Patients
Terumo BCTbio2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2010年9月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- Change in Maximum Amplitude at 1-hour Post-transfusion
研究概览
简要总结
The PRESS trial is a single-center, two-part, randomized cross-over pilot study in Copenhagen that will evaluate 1) the safety and performance of Mirasol-treated and untreated platelet products stored for 2-4 days and for 7-days in Platelet Additive Solution (PAS) and 2) the correlation between the TEG® parameters and platelet count increments after platelet transfusions in thrombocytopenic subjects.
详细描述
- To evaluate in thrombocytopenic subjects the efficacy and safety of platelets treated with Mirasol Pathogen Reduction Technology (PRT) in Platelet Additive Solution. The following safety and efficacy measures will be compared between Mirasol treated and untreated platelets stored for 2-4 days and stored for 7 days:
- Thrombelastography (TEG®) parameters: reaction time R, alpha angle α and maximal amplitude (MA)
- Platelet Count Increment and Corrected Count Increment
- Time to next platelet transfusion
- Incidence of transfusion related (serious) adverse events
- Incidence and severity of bleedings
- To evaluate the use of the TEG® parameters as a measure for platelet transfusion efficacy and to evaluate the correlation between the TEG® parameters and the platelet Corrected Count Increments after platelet transfusions in thrombocytopenic subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female of age of 18 years or older.
- •Have thrombocytopenia or expected to develop thrombocytopenia requiring at least 3 platelet transfusions.
- •Woman of child bearing potential must have a negative serum or urine pregnancy test within 72 hours before randomization.
- •Subjects must have signed and dated the Informed Consent Form before performing any protocol related procedure.
排除标准
- •History of any hypersensitivity reaction to riboflavin or metabolites.
- •History of refractoriness to platelet transfusions (defined as 2 successive CCI1hr<5000) or presence of human leukocyte antigen (HLA) antibodies or positive lymphocytotoxicity or previously documented alloimmunization.
- •Previous exposure to PRT-treated platelet concentrates.
- •Active bleeding requiring one or more red cells concentrate transfusions (i.e. grade 3 or 4 bleeding according to the WHO bleeding assessment scale in Appendix 1).
- •Exposure to an investigational product, within 30 days before randomization.
- •Splenomegaly (presence of a palpable spleen whose border could be felt more than 4 cm below the costal margin) or splenectomy.
- •History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura (ITP), Thrombotic Thrombocytopenia Purpura (TTP), or Haemolytic Uremic Syndrome (HUS).
- •Use of prohibited medication (see section 5.5).
- •Pregnant or lactating females.
- •Any medical condition or treatment that would be expected to compromise the effectiveness of a platelet transfusion or that would interfere with an expected platelet count increment.
- •Any other medical condition that would compromise the participation of the subject in the study.
结局指标
主要结局
Change in Maximum Amplitude at 1-hour Post-transfusion
时间窗: pre-transfusion, 1-hour post transfusion
Thromboelastography (TEG) Parameter: Pre- to post-transfusional modification of Maximum Amplitude at 1-hour post-transfusion
次要结局
- Change in Maximum Amplitude at 24-hours Post-transfusion(pre-transfusion, 24-hour post transfusion)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
2 期
Combination of Toripalimab and JS004 Therapy for ccRCCClear Cell Renal Cell CarcinomaNCT06690697Fudan University80
终止
2 期
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)Metastatic Breast CancerNCT00434356Genentech, Inc.46
终止
2 期
A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)ChondrosarcomaNCT00543712Genentech, Inc.15
已完成
1 期
Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.Smoking, CigaretteNCT03362008Jeil Pharmaceutical Co., Ltd.31
Unknown
不适用
Improving the Accuracy of Referrals of Patients With Chest PainChest PainHeart AttackMyocardial InfarctionAcute Coronary SyndromeMyocardial IschemiaNCT04904107VieCuri Medical Centre852